We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+30.09%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$944M
AUM Growth
–
Cap. Flow
+$791M
Cap. Flow %
83.77%
Top 10 Hldgs %
61.64%
Holding
48
New
48
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$92.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$90.5M
3
ASND icon
Ascendis Pharma A/S
ASND
+$62.3M
4
MRK icon
Merck
MRK
+$41.5M
5
GMED icon
Globus Medical
GMED
+$39M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
26
Jade Biosciences
JBIO
$1.35B
$9.05M 0.96%
+11,429
New +$5.82M
REGN icon
27
Regeneron Pharmaceuticals
REGN
$79.5B
$8.78M 0.93%
+10,000
New +$8.23M
ARQT icon
28
Arcutis Biotherapeutics
ARQT
$3.31B
$8.72M 0.92%
+2,700,000
New +$7.34M
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.24B
$8.06M 0.85%
+175,000
New +$6.18M
FULC icon
30
Fulcrum Therapeutics
FULC
$288M
$6.92M 0.73%
+1,025,000
New +$4.55M
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$28.9B
$6.7M 0.71%
+35,000
New +$5.96M
LKFT
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$5.28M 0.56%
+130,000
New +$4.78M
FATE icon
33
Fate Therapeutics
FATE
$290M
$4.82M 0.51%
+1,290,000
New +$3.05M
CYTK icon
34
Cytokinetics
CYTK
$11B
$4.17M 0.44%
+50,000
New +$1.81M
ACLX
35
DELISTED
Arcellx
ACLX
$3.33M 0.35%
+60,000
New +$2.71M
BLUE
36
DELISTED
bluebird bio
BLUE
$2.97M 0.31%
+107,500
New +$6.55M
TEVA icon
37
Teva Pharmaceuticals
TEVA
$40.6B
$2.09M 0.22%
+200,000
New +$1.87M
DNTH icon
38
Dianthus Therapeutics
DNTH
$6.15B
$1.4M 0.15%
+135,000
New +$1.49M
CMRX
39
DELISTED
Chimerix, Inc.
CMRX
$1.35M 0.14%
+1,400,000
New +$1.36M
PYXS icon
40
Pyxis Oncology
PYXS
$238M
$792K 0.08%
+440,000
New +$754K
OKUR
41
OnKure Therapeutics
OKUR
$168M
$640K 0.07%
+40,000
New +$2.49M
IMA
42
ImageneBio Inc
IMA
$64M
$636K 0.07%
+26,889
New +$877K
RLMD icon
43
Relmada Therapeutics
RLMD
$564M
$476K 0.05%
+115,000
New +$340K
AFMD
44
DELISTED
Affimed
AFMD
$341K 0.04%
+54,607
New +$227K
OVID icon
45
Ovid Therapeutics
OVID
$495M
$275K 0.03%
+85,429
New +$292K
SLDB icon
46
Solid Biosciences
SLDB
$857M
$209K 0.02%
+34,085
New +$109K
PRME icon
47
Prime Medicine
PRME
$533M
$180K 0.02%
+20,306
New +$156K
ACHL
48
DELISTED
Achilles Therapeutics
ACHL
$96.1K 0.01%
+108,083
New +$92.7K
1
2

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Vestal Point Capital, which disclosed 48 positions worth $944M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Neurocrine Biosciences: 800,000 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Vestal Point Capital's largest Q4 2023 buy was Neurocrine Biosciences: 800,000 shares worth $105M.
  • Vestal Point Capital's ten largest holdings make up 62% of its $944M portfolio in Q4 2023.
  • Vestal Point Capital disclosed 48 positions in Q4 2023, its first 13F filing on record.

Based on Vestal Point Capital's 13F filing for Q4 2023, filed 13 Feb 2024.